Clinical Trials Browser

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

NCT02738866 2025-12-10

Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

Phase 2 Active not recruiting

60 enrolled

Breast

Breast Neoplasms

NCT05226871 2025-11-25

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

Phase 2 Active not recruiting

35 enrolled

BreastHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms

NCT04214288 2025-11-20

SERENA-2

Phase 2 Active not recruiting

240 enrolled 16 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT05090358 2025-10-27

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

Phase 2 Active not recruiting

15 enrolled

Breast

Breast Neoplasms

NCT04557449 2025-10-01

CDK4i

Phase 2 Active not recruiting

362 enrolled

BreastGastrointestinalGenitourinarySarcomaThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

NCT03147287 2025-09-30

Palbociclib After CDK and Endocrine Therapy (PACE)

Phase 2 Active not recruiting

220 enrolled 11 charts

Breast

Breast Neoplasms

NCT05392608 2025-09-17

SEQUEL-Breast

Phase 2 Active not recruiting

130 enrolled

Breast

Breast Neoplasms, Genetic Diseases, Inborn

NCT05625087 2025-08-20

SAFIR 03

Phase 2 Active not recruiting

162 enrolled

Breast

Breast Neoplasms

NCT00585507 2025-07-10

Efficacy and Safety of 500mg of Fulvestrant

Phase 2 Active not recruiting

40 enrolled

Breast

Breast Neoplasms

NCT02955394 2025-07-09

Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

Phase 2 Active not recruiting

61 enrolled 12 charts

Breast

Breast Neoplasms

NCT05463601 2025-05-14

Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

Phase 2 Active not recruiting

132 enrolled

Breast

Breast Neoplasms

NCT06957379 2025-05-04

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

Phase 2 Active not recruiting

78 enrolled

Breast

Breast Neoplasms

NCT04053322 2025-03-12

DOLAF

Phase 2 Active not recruiting

172 enrolled

Breast

ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer

Clinical Trials

FAIM

PF-07104091 as a Single Agent and in Combination Therapy

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

SERENA-2

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

CDK4i

Palbociclib After CDK and Endocrine Therapy (PACE)

SEQUEL-Breast

SAFIR 03

Efficacy and Safety of 500mg of Fulvestrant

Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

DOLAF